Education
About Us
Working with TipRanks
Follow Us
BioMark Diagnostics (TSE:BUX)
:BUX
RESEARCH TOOLSreports
BUX Stock Chart & Stats
Day’s Range― - ―
52-Week RangeC$0.18 - C$0.35
Previous CloseN/A
Volume0.00
Average Volume (3M)14.63K
Market Cap
C$29.99M
Enterprise ValueN/A
Total Cash (Recent Filing)C$88.58K
Total Debt (Recent Filing)C$546.53K
Price to Earnings (P/E)―
Beta-0.35
Next Earnings
Jul 09, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding90,886,230
10 Day Avg. Volume11,700
30 Day Avg. Volume14,625
Financial Highlights & Ratios
PEG Ratio-2.64
Price to Book (P/B)-18.63
Price to Sales (P/S)0.00
P/FCF Ratio-25.38
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
BioMark Diagnostics News
PremiumCompany Announcements
BioMark Diagnostics Unveils AI Breakthrough in Early Lung Cancer Detection
PremiumCompany Announcements
BioMark Diagnostics Validates High Accuracy of Early-Stage Lung Cancer Test
PremiumCompany Announcements
BioMark Diagnostics Uplists to OTCQB, Boosting U.S. Market Presence
PremiumCompany Announcements
BioMark’s Breakthrough in Breast Cancer Diagnosis
PremiumCompany Announcements
BioMark Advances in Breast Cancer Detection TechnologyOptions Prices
Currently, No data available
---
Ownership Overview
55.44% Insiders
―
Mutual Funds
― Other Institutional Investors
44.56% Public Companies and
Individual Investors
BUX FAQ
What was BioMark Diagnostics’s price range in the past 12 months?
BioMark Diagnostics lowest stock price was C$0.18 and its highest was C$0.35 in the past 12 months.
What is BioMark Diagnostics’s market cap?
BioMark Diagnostics’s market cap is C$29.99M.
When is BioMark Diagnostics’s upcoming earnings report date?
BioMark Diagnostics’s upcoming earnings report date is Jul 09, 2025 which is in 3 days.
How were BioMark Diagnostics’s earnings last quarter?
BioMark Diagnostics released its earnings results on Mar 01, 2025. The company reported -C$0.004 earnings per share for the quarter, missing the consensus estimate of N/A by -C$0.004.
Is BioMark Diagnostics overvalued?
According to Wall Street analysts BioMark Diagnostics’s price is currently Overvalued.
Does BioMark Diagnostics pay dividends?
BioMark Diagnostics does not currently pay dividends.
What is BioMark Diagnostics’s EPS estimate?
BioMark Diagnostics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does BioMark Diagnostics have?
BioMark Diagnostics has 90,886,230 shares outstanding.
What happened to BioMark Diagnostics’s price movement after its last earnings report?
BioMark Diagnostics reported an EPS of -C$0.004 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of BioMark Diagnostics?
Currently, no hedge funds are holding shares in TSE:BUX
Company Description
BioMark Diagnostics
BioMark Diagnostics (BUX) is a biotechnology company focused on developing advanced diagnostic solutions in the oncology sector. The company specializes in the detection and monitoring of cancer through its proprietary metabolomics-based technology, which aims to provide non-invasive, accurate, and cost-effective diagnostic tools for early cancer detection and treatment monitoring.